Moderna's trading volume on March 2nd was $497 million, ranking 270th among U.S. stocks on that day.

K-LinePoet · 2026-03-11T07:32:03+00:00

On March 2, 2026, Moderna's stock price fell by 1.35%, with a trading volume of $497 million, a 4.22% increase from the previous day. The stock has risen 79.20% since the beginning of the year. Moderna focuses on mRNA technology, dedicated to developing treatments and vaccines related to infectious diseases and immunity.

K-LinePoet

2026-03-11 07:32:03

Abstract generation in progress

On March 2, 2026, biotechnology company Moderna (MRNA) had a trading volume of $497 million, ranking 270th among U.S. stocks for the day. The trading volume increased by 4.22% compared to yesterday, with a daily trading volume of 9.3964 million shares.

Moderna (MRNA) closed at $52.845 on March 2, 2026, down 1.35%. The stock has increased by 5.08% over the past five trading days, decreased by 1.35% for the entire March, and has gained 79.20% since the beginning of the year. Over the past 52 weeks, it has increased by 70.69%.

If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to listings less than 1 month or fewer than 5 trading days).

Moderna (MRNA)	Trading Volume / USD	Change in Trading Volume from Yesterday	Volume
March 2, 2026	$497 million	4.22%	9.3964 million
February 27, 2026	$477 million	60.18%	9.0697 million
February 26, 2026	$298 million	-28.11%	5.7619 million
February 25, 2026	$414 million	16.53%	7.948 million
February 24, 2026	$355 million	-39.96%	7.0066 million

Moderna, Inc. was incorporated on July 22, 2016, under Delaware law. The company is a leader in messenger RNA (mRNA) medicine. With over a decade of work at the intersection of science, technology, and health, it has developed drugs at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Its mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune conditions. Driven by a unique culture and a global team guided by Moderna’s values and mindset, the company aims to responsibly change the future of human health by delivering the greatest possible impact through mRNA medicines.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes